Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth

Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials as a promising therapeutic modality. Venetocla...

Descripción completa

Detalles Bibliográficos
Autores principales: Velentza, Lilly, Wickström, Malin, Kogner, Per, Ohlsson, Claes, Zaman, Farasat, Sävendahl, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192431/
https://www.ncbi.nlm.nih.gov/pubmed/37198212
http://dx.doi.org/10.1038/s41598-023-34965-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192431/
https://www.ncbi.nlm.nih.gov/pubmed/37198212
http://dx.doi.org/10.1038/s41598-023-34965-4

Ejemplares similares